Literature DB >> 26362716

miR-506 Inhibits Epithelial-to-Mesenchymal Transition and Angiogenesis in Gastric Cancer.

Zhen Li1, Zhimin Liu2, Suwei Dong1, Jianhua Zhang2, Jing Tan3, Ying Wang2, Chunlei Ge2, Ruilei Li2, Yuanbo Xue2, Mei Li4, Weiwei Wang5, Xudong Xiang5, Jinyan Yang2, Haiyan Ding2, Tao Geng2, Kaitai Yao6, Xin Song7.   

Abstract

Gastric cancer is one of the most common malignancies in developing countries. We examined the possible role of miR-506 in gastric cancer, investigated its associations with the clinical outcomes of gastric cancer patients, and explored its potential role in angiogenesis and the metastasis of gastric cancer cells. We found that miR-506 expression was a useful marker for stratifying patients from early to advanced clinical stages and for overall survival prediction. miR-506 overexpression inhibited the epithelial-to-mesenchymal transition of gastric cancer cells; however, depletion of miR-506 promoted it. In addition, miR-506 suppressed gastric cancer angiogenesis and was associated with decreased matrix metalloproteinase-9 expression. We also found that ETS1 was a miR-506 target, and it was expressed in 71.10% of gastric cancer tissue samples. Moreover, ETS1 expression was associated with matrix metalloproteinase-9 expression (P < 0.001). In conclusion, miR-506 was identified as an ETS1 targeting suppressor of metastatic invasion and angiogenesis in gastric cancer.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26362716     DOI: 10.1016/j.ajpath.2015.05.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  Differential expression of PDGFRB and EGFR in microvascular proliferation in glioblastoma.

Authors:  Guiyan Xu; Jian Yi Li
Journal:  Tumour Biol       Date:  2016-02-09

2.  miR-506 contributes to malignancy of cutaneous squamous cell carcinoma via targeting of P65 and LAMC1.

Authors:  Jian Zhou; Ying Zhang; Zhaofeng Han; Zhiwei Dong; Tongtong Cao; Aizhou Wei; Pengfei Guo; Qingnan Meng
Journal:  Cell Cycle       Date:  2019-01-24       Impact factor: 4.534

Review 3.  Ran GTPase: A Key Player in Tumor Progression and Metastasis.

Authors:  Zied Boudhraa; Euridice Carmona; Diane Provencher; Anne-Marie Mes-Masson
Journal:  Front Cell Dev Biol       Date:  2020-05-26

Review 4.  Angiogenesis-related non-coding RNAs and gastrointestinal cancer.

Authors:  Zahra Sadat Razavi; Kasra Asgarpour; Maryam Mahjoubin-Tehran; Susan Rasouli; Haroon Khan; Mohammad Karim Shahrzad; Michael R Hamblin; Hamed Mirzaei
Journal:  Mol Ther Oncolytics       Date:  2021-05-15       Impact factor: 7.200

5.  MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression.

Authors:  Run-Fen Cheng; Jian Wang; Jing-Yi Zhang; Lin Sun; Yan-Rui Zhao; Zhi-Qiang Qiu; Bao-Cun Sun; Yan Sun
Journal:  Chin J Cancer       Date:  2016-07-02

6.  Plasma miRNA-506 as a Prognostic Biomarker for Esophageal Squamous Cell Carcinoma.

Authors:  Shu-Ping Li; Hong-Xin Su; Da Zhao; Quan-Lin Guan
Journal:  Med Sci Monit       Date:  2016-06-27

7.  Overexpression of microRNA-506-3p aggravates the injury of vascular endothelial cells in patients with hypertension by downregulating Beclin1 expression.

Authors:  Fanfan Yi; Yugui Hao; Xiaoyi Chong; Wei Zhong
Journal:  Exp Ther Med       Date:  2018-01-10       Impact factor: 2.447

8.  Prognostic value of microRNAs in gastric cancer: a meta-analysis.

Authors:  Yue Zhang; Dong-Hui Guan; Rong-Xiu Bi; Jin Xie; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-06-21

Review 9.  The emerging role of miR-506 in cancer.

Authors:  Jian Li; Jingfang Ju; Bing Ni; Huaizhi Wang
Journal:  Oncotarget       Date:  2016-09-20

Review 10.  The role of miRNA and lncRNA in gastric cancer.

Authors:  Ning-Bo Hao; Ya-Fei He; Xiao-Qin Li; Kai Wang; Rui-Ling Wang
Journal:  Oncotarget       Date:  2017-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.